To evaluate the efficacy and safety of intracameral triamcinolone acetonide (TA) in glaucoma surgery.Prospective randomized clinical trial.setting: Institutional—Wills Eye Hospital. study population: Patients undergoing trabeculectomy (with or without cataract surgery) or tube shunt surgery. intervention: Patients were randomized to receive intracameral TA or balanced salt solution at the end of surgery. Follow-up time was 6 months. main outcome measures: Intraocular pressure, visual acuity, inflammation measured by slit-lamp examination and laser flare meter, cataract grading, bleb appearance, dry eye scores, use of supplemental medical therapy, surgical success, and rate of complications.Seventy-seven patients were enrolled in the study, including 37 in the TA group and 40 in the control group. There were no significant differences in success rates between the 2 groups (P = .60). Intraocular pressure and medication use were similar between the groups for each follow-up visit. Dry eye scores were lower in the TA group at month 1 (P = .042), while flare scores were higher in the TA group on day 1 (P = .015) but lower at month 1 (P = .044). The complication rates were higher in the TA group on day 1 (P = .04). All other outcome measures were similar for both groups.Intracameral TA did not affect the success rates or change the complication rates of glaucoma surgery.